Subscribe
novartis-building-slider
18 August 2020Big PharmaMuireann Bolger

Novartis secures victory as MS drug patent is upheld

In a win for  Novartis Pharmaceuticals, the  US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug  Gilenya.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Novartis MS drug appeal upheld in Australia
13 October 2020   The Federal Court of Australia has backed Novartis’ appeal against a decision revoking its patent covering a multiple sclerosis drug.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
Americas
AbbVie fights to invalidate Novartis patents
3 April 2017   AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Novartis MS drug appeal upheld in Australia
13 October 2020   The Federal Court of Australia has backed Novartis’ appeal against a decision revoking its patent covering a multiple sclerosis drug.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
Americas
AbbVie fights to invalidate Novartis patents
3 April 2017   AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.

More on this story

Big Pharma
Novartis MS drug appeal upheld in Australia
13 October 2020   The Federal Court of Australia has backed Novartis’ appeal against a decision revoking its patent covering a multiple sclerosis drug.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
Americas
AbbVie fights to invalidate Novartis patents
3 April 2017   AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB